DECHENG CAPITAL GLOBAL LIFE SCIENCES FUND IV, L.P. purchased 1.25M shares of AARDVARK THERAPEUTICS, INC. on the open market
Open‑market purchase worth $20.00M. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 2/19/2025ACC: 0000950170-25-023409
→
10% Owner
Since Feb 2025
-18.69M
Net shares
Net seller
$20.00M
Total acquired
2
Open market trades
2B · 0S
6
Total transactions
3.92M acquired · 22.60M disposed
Non-Derivative Transactions4
Common Stock
Indirect
Shares
+2.33M
Price / share
—
Trade value
—
% of position
New position
2/14/2025
0.00→2.33M
Common Stock
Indirect
Shares
+333.41K
Price / share
—
Trade value
—
% of position
New position
2/14/2025
0.00→333.41K
Common Stock
Indirect
Shares
+625K
Price / share
$16.00
Trade value
$10M
% of position
26.8%
2/14/2025
2.33M→2.96M
Common Stock
Indirect
Shares
+625K
Price / share
$16.00
Trade value
$10M
% of position
187.5%
2/14/2025
333.41K→958.41K
Total
Net shares
+3.92M
Net value
$20M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 2/14/2025 | C · Conversion | +2.33M | — | — | New position | 0.00 | 2.33M |
| Common Stock Indirect | 2/14/2025 | C · Conversion | +333.41K | — | — | New position | 0.00 | 333.41K |
| Common Stock Indirect | 2/14/2025 | P · Purchase | +625K | $16.00 | $10M | 26.8% | 2.33M | 2.96M |
| Common Stock Indirect | 2/14/2025 | P · Purchase | +625K | $16.00 | $10M | 187.5% | 333.41K | 958.41K |
| Total | +3.92M | $20M | ||||||
Derivative Transactions2
Series C Convertible Preferred Stock
Indirect
Converts to
Common Stock
2.33M shares
Shares
−19.78M
Strike price
Held after
0.00
Exercisable
—
2/14/2025
Series C Convertible Preferred Stock
Indirect
Converts to
Common Stock
333.41K shares
Shares
−2.83M
Strike price
Held after
0.00
Exercisable
—
2/14/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Series C Convertible Preferred Stock Indirect | Common Stock2.33M shares | 2/14/2025 | C · Conversion | −19.78M | — | 0.00 | |
| Series C Convertible Preferred Stock Indirect | Common Stock333.41K shares | 2/14/2025 | C · Conversion | −2.83M | — | 0.00 |